These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 17516396)

  • 1. Counterpoint: Vancomycin and Staphylococcus aureus--an antibiotic enters obsolescence.
    Deresinski S
    Clin Infect Dis; 2007 Jun; 44(12):1543-8. PubMed ID: 17516396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Point: Vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus.
    Mohr JF; Murray BE
    Clin Infect Dis; 2007 Jun; 44(12):1536-42. PubMed ID: 17516395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is vancomycin obsolete?
    Legendre D
    Am J Health Syst Pharm; 2009 Jun; 66(11):977-8. PubMed ID: 19451604
    [No Abstract]   [Full Text] [Related]  

  • 4. Monitoring of vancomycin serum levels for the treatment of staphylococcal infections.
    Kitzis MD; Goldstein FW
    Clin Microbiol Infect; 2006 Jan; 12(1):92-5. PubMed ID: 16460555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vancomycin: does it still have a role as an antistaphylococcal agent?
    Deresinski S
    Expert Rev Anti Infect Ther; 2007 Jun; 5(3):393-401. PubMed ID: 17547504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of severe infections caused by Staphylococcus aureus: a change in the vancomycin paradigm?
    Aranha Camargo LF
    Shock; 2008 Oct; 30 Suppl 1():67-9. PubMed ID: 18704006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains.
    Sakoulas G; Moellering RC
    Clin Infect Dis; 2008 Jun; 46 Suppl 5():S360-7. PubMed ID: 18462091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multidrug and vancomycin resistance among clinical isolates of
    Olufunmiso O; Tolulope I; Roger C
    Afr Health Sci; 2017 Sep; 17(3):797-807. PubMed ID: 29085408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic effect of ME1036 on endocarditis experimentally induced by methicillin-resistant Staphylococcus aureus.
    Nagura J; Kijima K; Kurazono M; Takahata S; Sugano T; Tanaka Y; Hirai Y; Yamada K; Takayama Y; Shitara E; Yonezawa M
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3526-8. PubMed ID: 16048975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model.
    Jacqueline C; Caillon J; Le Mabecque V; Miègeville AF; Hamel A; Bugnon D; Ge JY; Potel G
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3397-400. PubMed ID: 17591849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vancomycin-resistant Staphylococcus aureus.
    Lessing MP; Raftery MJ
    Lancet; 1998 Feb; 351(9102):601-2. PubMed ID: 9492813
    [No Abstract]   [Full Text] [Related]  

  • 12. Methicillin-resistant Staphylococcus aureus pneumonia treatment: do not confuse pharmacokinetics and pharmacodynamics.
    Moine P; Bédos JP
    Chest; 2007 Sep; 132(3):1101, author reply 1102-3. PubMed ID: 17873216
    [No Abstract]   [Full Text] [Related]  

  • 13. Key considerations in the treatment of complicated staphylococcal infections.
    Jones RN
    Clin Microbiol Infect; 2008 Mar; 14 Suppl 2():3-9. PubMed ID: 18226084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus.
    Madrigal AG; Basuino L; Chambers HF
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3163-5. PubMed ID: 16048918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. D-cycloserine increases the effectiveness of vancomycin against vancomycin-highly resistant Staphylococcus aureus.
    Tabuchi F; Matsumoto Y; Ishii M; Tatsuno K; Okazaki M; Sato T; Moriya K; Sekimizu K
    J Antibiot (Tokyo); 2017 Jul; 70(8):907-910. PubMed ID: 28588223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical implications of vancomycin heteroresistant and intermediately susceptible Staphylococcus aureus.
    Gomes DM; Ward KE; LaPlante KL
    Pharmacotherapy; 2015 Apr; 35(4):424-32. PubMed ID: 25884530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro evaluation of antibiotics' combinations for empirical therapy of suspected methicillin resistant Staphylococcus aureus severe respiratory infections.
    Drago L; De Vecchi E; Nicola L; Gismondo MR
    BMC Infect Dis; 2007 Sep; 7():111. PubMed ID: 17888153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of methicillin-resistant Staphylococcus aureus in neonatal mice: lysostaphin versus vancomycin.
    Placencia FX; Kong L; Weisman LE
    Pediatr Res; 2009 Apr; 65(4):420-4. PubMed ID: 19127212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro and in vivo bactericidal activities of vancomycin dispersed in porous biodegradable poly(epsilon-caprolactone) microparticles.
    Le Ray AM; Gautier H; Laty MK; Daculsi G; Merle C; Jacqueline C; Hamel A; Caillon J
    Antimicrob Agents Chemother; 2005 Jul; 49(7):3025-7. PubMed ID: 15980391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group.
    Smith TL; Pearson ML; Wilcox KR; Cruz C; Lancaster MV; Robinson-Dunn B; Tenover FC; Zervos MJ; Band JD; White E; Jarvis WR
    N Engl J Med; 1999 Feb; 340(7):493-501. PubMed ID: 10021469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.